Key result
Cancer patients with ACS receive ~26% less PCA than controls and face higher in-hospital mortality.
Why the study?
Anticancer therapies can cause cardiovascular complications including ACS, and cancer may influence ACS therapeutic decisions.
Does the presence of active or recent cancer treatment influence the clinical presentation and invasive management of acute coronary syndrome?
Case-Control (n=64)
No
Does the presence of active or recent cancer treatment influence the clinical presentation and invasive management of acute coronary syndrome?
Absolute Event Rate: 53% vs 72%
Patients with cancer presenting with acute coronary syndrome are less likely to receive guideline-directed invasive management such as coronary angiography and PCI compared to matched non-cancer patients.
Cancer patients with ACS receive less invasive care; observational data leaves open whether guideline-directed strategies improve outcomes in this population.
No takes yet. Share an insight, caveat, or question.
Nabiałek-Trojanowska et al. (2019) conducted a case-control in Acute coronary syndrome (n=64). Active or recent anticancer treatment vs. No cancer diagnosis was evaluated on Percutaneous coronary angioplasty (PCA) performance. Cancer patients admitted with ACS were less likely to undergo percutaneous coronary angioplasty than matched controls (53% vs 72%) and had higher in-hospital mortality (6.25% vs 0%).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: